Epstein Secrets

led in Feb (unchanged from Jan vs estimate 40.6%) Marks & Spencer gains the most in six months as sales fall less than estimated (trading 45.47%) Novartis asks EU regulators to approve the Prexige pain pill that was pulled off the market 4 years ago German factory orders climb almost 5x faster than es

ounced/priced): KRC, 2BB, DLLR IPO's (filed/priced): Pimco REIT files $600M through CS, GS & JPM, IPO's (lock-up expires): EFC, GEDU Key Research: Macquarie initiates US Clinical Diagnostic Labs - BRLI/MYGN (neutral) & GHDX/LH/DGX (op) Key Research: MS initiates SRCL (ew), HSBC upgrades global financial

ar, LFL's strong (trading -0.16%) • Astrazeneca eps slightly lower than estimates, maintains guidance, pipeline update positive (trading +4.0%) • Novartis O1 core eps and net meet estimates, fx impact, sales miss, guidance reiterated (trading -1.1%) • Novozymes Q1 beats estimates, now sees 2014 net pr

nitiates YY (buy), KBW upgrades CFR ir Key downgrades FR, Opco upgrades HMSY, BMO initiates NXPI (op) ••• Bofa downgrades SCCO, Raja upgrades OKSB, Macquarie downgrades SUSS ••• Susquehanna initiates XRX (pos), UBS upgrades CIEN (buy), CLSA upgrades AAPL (buy) Europe Key Research: ••• Bofa initiates GMS

e reporting inline with recent pre-announcement and guiding touch lower). Healthcare +1.28% & Food/Beverages +0.72% also outperforming in Europe as Novartis +3.8% & Unilever +2.4% break-out after reporting solid numbers. Volumes heavy across the region with Estoxx600 turnover currently —130% of 3-month a

h: • Barcap upgrades UNM & initiates ALLT (ow), DB downgrades F, Imperial initiates EAGL (op) • Jeff initiates HRG (buy) & reiterates buy for GOOG, Macquarie upgrades Honda Motor (7267 JP) • Piper initiates ELX/OLGC (neut's) & MLNX (ow), Raja upgrades DHI/KBH, CLSA downgrades DD ••• Davenport downgrades